From: Amyloid PET imaging in multiple sclerosis: an 18F-florbetaben study
Patients | PV-1 | PV-2 | JC-1 | JC-2 | NAWM | NAWM |
---|---|---|---|---|---|---|
1 | 1.28 | 0.86 | 1.07 | 0.96 | 1.58 | 1.56 |
2 | 0.83 | 0.93 | 0.93 | 0.94 | 1.41 | 1.27 |
3 | 1.68 | 1.52 | 1.51 | 1.35 | 2.09 | 2.10 |
4 | 1.38 | 1.40 | 0.78 | 1.61 | 1.61 | 1.86 |
5 | 1.47 | 1.50 | 1.57 | 2.02 | 2.12 | 2.28 |
6 | 1.27 | 1.04 | 1.66 | 1.75 | 2.07 | 2.27 |
7 | 0.90 | 1.54 | 1.57 | 1.61 | 1.77 | 1.78 |
8 | 1.30 | 1.47 | 0.82 | 1.17 | 1.76 | 2.13 |
9 | 1.11 | 1.12 | 0.91 | 1.01 | 1.42 | 1.49 |
10 | 1.20 | 0.97 | 1.32 | 0.90 | 1.70 | 1.57 |
11 | 1.29 | 1.52 | 0.96 | 1.10 | 1.78 | 1.69 |
12 | 1.12 | 1.23 | 1.28 | 1.31 | 1.52 | 1.60 |
Control 1 | - | - | - | - | 2.35 | 2.25 |
Control 2 | - | - | - | - | 2.30 | 2.39 |
Control 3 | - | - | - | - | 2.37 | 2.51 |